New approaches in palliative systemic therapy of anal squamous cell carcinoma | Zendy

Radka Lohynská | Zendy; Zdeňka Pechačová | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New approaches in palliative systemic therapy of anal squamous cell carcinoma

Author(s) -

Radka Lohynská,

Zdeňka Pechačová

Publication year - 2022

Publication title -

klinicka onkologie

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.204

H-Index - 13

eISSN - 1802-5307

pISSN - 0862-495X

DOI - 10.48095/ccko2022190

Subject(s) - medicine , docetaxel , oncology , regimen , palliative care , chemotherapy , carboplatin , immunotherapy , systemic therapy , cisplatin , cancer , breast cancer , nursing

Metastatic and locally recurrent inoperable anal squamous cell carcinoma (ASCC) belong to rare tumours - ASCC accounts for about 2% of gastrointestinal tumours. Synchronous metastatic involvement is usually confirmed in approximately 15% of patients and about 20 % of patients develop relapse in the form of distant metastases after curative treatment. The current standard palliative systemic treatment is a PF regimen composed of 5-fluorouracil (5-FU) with cisplatin (cDDP) or a combination of carboplatin with paclitaxel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research